

1199 SEIU Benefit Funds
Medical Oncology Code List

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact 1199 SEIU Benefit Funds or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
5-Fluorouracil - Topical	5FU Cream, Efudex, Carac, Fluoroplex	J3490	Medical Oncology - CHEMO	Primary	TOPICAL	Y		
5-Fluorouracil- Injection	5FU, Adrucil	J9190	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Abemaciclib - oral	Verzenio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Abiraterone Acetate - oral	Yonsa (not interchangeable with Zytiga)	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Abiraterone Acetate - oral	Zytiga (not interchangeable with Yonsa)	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Acalabrutinib - oral	Calquence	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Acitretin - oral	Soriatane	J8499	Medical Oncology - CHEMO	Primary	ORAL	Y		
Adagrasib - oral	Krazati	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ado-Trastuzumab Emtansine	Kadcyla	J9354	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Afatinib - oral	Gilotrif	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Aldesleukin	Proleukin, Interleukin-2	J9015	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Alectinib - oral	Alecensa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
All-trans Retinoic Acid - oral	Vesanoid, ATRA, Tretinoin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Alpelisib - oral	Piqray	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Amivantamab-vmjw	Rybrevant	J9061	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Apalutamide - oral	Erleada	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Aprepitant	Cinvanti	J0185	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Aprepitant - oral	Emend	J8501	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y		
Arsenic Trioxide	Trisenox	J9017	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Asciminib - oral	Scemblix	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Asparaginase	Erwinaze	J9019	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze	J9021	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Atezolizumab	Tecentriq	J9022	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Avapritinib - oral	Ayvakit	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Avelumab	Bavencio	J9023	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Axitinib - oral	Inlyta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Azacitidine	Vidaza	J9025	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Azacitidine - oral	Onureg	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B
BCG	TheraCys, Tice	J9030	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Belantamab Mafodotin-blmf	Blenrep	J9037	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Belinostat	Beleodaq	J9032	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Belzutifan - oral	Welireg	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Bendamustine HCL	Belrapzo	J9036	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bendamustine HCL	Bendeka	J9034	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bendamustine HCL	Treanda	J9033	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bendamustine HCL (apotex)		J9058	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bendamustine HCL (baxter)		J9059	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bendamustine HCL (vivimusta)		J9056	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bevacizumab	Avastin	J9035	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Bevacizumab (Radiation Necrosis)	Avastin	J9035	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	Supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		Supportive pathway for the use of Vegzelma to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bevacizumab-awwb	Mvasi	Q5107	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Bevacizumab-awwb (Radiation Necrosis)	Mvasi	Q5107	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	Supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	Supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Bevacizumab-maly	Alymysys	Q5126	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Bevacizumab-maly (Radiation Necrosis)	Alymysys	Q5126	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	Supportive pathway for the use of Alymysys to treat Radiation Induced Necrosis of the CNS
Bevacizumab-tnjin	Avzivi	C9399	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	New primary biosimilar chemotherapy drug for bevacizumab.
Bevacizumab-tnjin	Avzivi	J3490	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	New primary biosimilar chemotherapy drug for bevacizumab.

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Bevacizumab-tjnj	Avzivi	J3590	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	New primary biosimilar chemotherapy drug for bevacizumab.
Bevacizumab-tjnj	Avzivi	J9999	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	New primary biosimilar chemotherapy drug for bevacizumab.
Bevacizumab-tjnj	Avzivi	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	New supportive pathway for the use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bevacizumab-tjnj	Avzivi	J3490	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	New supportive pathway for the use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bevacizumab-tjnj	Avzivi	J3590	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	New supportive pathway for the use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bevacizumab-tjnj	Avzivi	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	New supportive pathway for the use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bexarotene - oral	Targretin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Bexarotene - topical	Targretin gel	C9399	Medical Oncology - CHEMO	Primary	TOPICAL	Y		
Bexarotene - topical	Targretin gel	J3490	Medical Oncology - CHEMO	Primary	TOPICAL	Y		
Binimetinib - oral	Mektovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Bleomycin	Blenoxane	J9040	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Blinatumomab	Blinicyto	J9039	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bortezomib	Velcade	J9041	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bortezomib (fresenius kabi)		J9048	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bortezomib (hospira)		J9049	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bortezomib (maia)		J9051	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Bosutinib - oral	Bosulif	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Brentuximab Vedotin	Adcetris	J9042	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Brigatinib - oral	Alunbrig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Burosumab-twza	Crysvita	J0584	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Cabazitaxel	Jevtana	J9043	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cabazitaxel (sandoz)		J9064	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cabozantinib - oral	Cabometyx	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Cabozantinib - oral	Cometriq	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Calaspargase pegol-mknl	Asparlas	J9118	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Capecitabine - oral	Xeloda (150 mg)	J8520	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B
Capecitabine - oral	Xeloda (500 mg)	J8521	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Capivasertib - oral	Truqap	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Capmatinib - oral	Tabrecta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Carboplatin	Paraplatin	J9045	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Carfilzomib	Kyprolis	J9047	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Carmustine	BICNU, BCNU	J9050	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Carmustine (accord)		J9052	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cemiplimab-rwlc	Libtayo	J9119	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ceritinib - oral	Zykadia	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Cetuximab	Erbixux	J9055	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Chlorambucil - oral	Leukeran	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	Medicare Part B
Chlorambucil - oral	Leukeran	S0172	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	Medicare Part B
Cisplatin	Platinol	J9060	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cladribine	Leustatin	J9065	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Clofarabine	Clolar	J9027	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cobimetinib - oral	Cotellic	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Crizotinib - oral	Xalkori	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Cyclophosphamide - inj	Cytoxan, Endoxan-Asta	J9070	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cyclophosphamide - inj (auromedic)		J9071	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cyclophosphamide - inj (dr. reddy's)		J9072	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cyclophosphamide - inj (ingenus)		J9073	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New manufacturer code: J9073 for Cyclophosphamide - inj, effective: 04/01/24
Cyclophosphamide - inj (sandoz)		J9074	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New manufacturer code: J9074 for Cyclophosphamide - inj, effective: 04/01/24
Cyclophosphamide Inj, not otherwise specified		J9075	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New generic HCPC Code: J9075 for Cyclophosphamide inj, effective: 04/01/24
Cytarabine	Ara-C	J9100	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Cytarabine-Liposome	DepoCyt	J9098	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Dabrafenib - oral	Tafinlar	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Dacarbazine	DTIC-Dome	J9130	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Dacomitinib - oral	Vizimpro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Dactinomycin	Cosmegen, Actinomycin	J9120	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Daratumumab	Darzalex	J9145	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Daratumumab and hyaluronidase-fihj	Darzalex Faspro	J9144	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Darbepoetin alfa	Aranesp	J0881	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Darolutamide - oral	Nubeqa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Dasatinib - oral	Sprycel	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Daunorubicin	Cerubidine	J9150	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Decitabine	Dacogen	J0894	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Decitabine (sun pharma)		J0893	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Decitabine and cedazuridine - oral	Inqovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Degarelix	Firmagon	J9155	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆ Excluding Xgeva	Primary chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.
Denosumab-bbdz	Wyost, Jubbonti	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	New supportive biosimilar for Xgeva and Prolia effective: 03/19/24
Denosumab-bbdz	Wyost, Jubbonti	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	New supportive biosimilar for Xgeva and Prolia effective: 03/19/24
Denosumab-bbdz	Wyost, Jubbonti	J3490	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	New supportive biosimilar for Xgeva and Prolia effective: 03/19/24
Denosumab-bbdz	Wyost, Jubbonti	J3590	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	New supportive biosimilar for Xgeva and Prolia effective: 03/19/24
Denosumab-bbdz	Wyost, Jubbonti	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆ Excluding Xgeva	New supportive biosimilar for Xgeva and Prolia effective: 03/19/24
Dinutuximab	Unituxin	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Dinutuximab	Unituxin	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Docetaxel	Taxotere	J9171	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Docetaxel (ingenus)		J9172	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Dolasetron Mesylate	Anzemet	J8597	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y		
Dostarlimab-gxly	Jemperli	J9272	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Doxorubicin HCL	Adriamycin	J9000	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Doxorubicin HCL (liposomal)	Doxil, Doxorubicin HCL (Liposomal) not otherwise specified	Q2050	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Durvalumab	Imfinzi	J9173	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Duvelisib - oral	Copiktra	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Efbemalenograstim alfa-vuxw	Ryzneuta	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Efbemalenograstim alfa-vuxw	Ryzneuta	J3490	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Efbemalenograstim alfa-vuxw	Ryzneuta	J3590	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Efbemalenograstim alfa-vuxw	Ryzneuta	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Eflapegrastim-xnst	Rolvedon	J1449	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Eflornithine - oral	Iwifin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		New primary oral chemotherapy drug effective: 01/04/24
Elacestrant - oral	Orserdu	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Elotuzumab	Empliciti	J9176	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Elranatamab-bcmm	Elrexio	J1323	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J1323 will replace NOC Code: C9165 & J9999 for Elrexio, effective: 04/01/24
Elranatamab-bcmm	Elrexio	C9165	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J1323 will replace NOC Code: C9165 & J9999 for Elrexio, effective: 04/01/24
Elranatamab-bcmm	Elrexio	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J1323 will replace NOC Code: C9165 & J9999 for Elrexio, effective: 04/01/24
Enasidenib - oral	IDHIFA	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Encorafenib - oral	Braftovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Enfortumab vedotin-efv	Padcev	J9177	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Entrectinib - oral	Rozlytrek	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Enzalutamide - oral	Xtandi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Eporitamab-bysp	Epkinly	J9321	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Epirubicin	Ellence	J9178	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Epoetin alfa	Epogen, Procrit	J0885	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Epoetin alfa-epbx	Retacrit	Q5106	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Erdafitinib-oral	Balversa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Eribulin mesylate	Halaven	J9179	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Erlotinib - oral	Tarceva	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Estramustine - oral	Emcyt	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Etoposide - inj	Toposar, VePesid, Etopophos	J9181	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Etoposide - oral	Toposar	J8560	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B
Everolimus - oral	Afinitor	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	
Fam-trastuzumab deruxtecan-nxki	Enhertu	J9358	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Fedratinib - oral	Inrebic	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Filgrastim	Neupogen	J1442	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Filgrastim-aafi	Nivestym	Q5110	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Filgrastim-ayow	Releuko	Q5125	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Filgrastim-sndz	Zarxio	Q5101	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Floxuridine	FUDR	J9200	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Fludarabine Phosphate	Fludara, Oforta	J9185	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Fluoxymesterone - oral	Androxy	J8499	Medical Oncology - CHEMO	Primary	ORAL	Y		
Fosaprepitant	Emend	J1453	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Fosaprepitant (focinvez)		J1434	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		New manufacturer code: J1434 for Fosaprepitant, effective: 04/01/24
Fosaprepitant (teva)		J1456	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Fosnetupitant/Palonosetron	Akynzeo	J1454	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Fruquintinib - oral	Fruzaqla	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Fulvestrant	Faslodex	J9395	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Fulvestrant (fresenius kabi)		J9394	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Fulvestrant (teva)		J9393	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Futibatinib - oral	Lytgobi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Gefitinib - oral	Iressa	J8565	Medical Oncology - CHEMO	Primary	ORAL	Y		
Gemcitabine	Gemzar	J9201	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Gemcitabine HCL in NaCL	Infugem	J9198	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Gemcitabine Hydrochloride (accord)		J9196	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Gemtuzumab Ozogamicin	Mylotarg	J9203	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Gilteritinib - oral	Xospata	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Glasdegib - oral	Daurismo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Glofitamab-gxbr	Columvi	J9286	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Goserelin acetate implant	Zoladex	J9202	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Granisetron - subcutaneous	Sustol	J1627	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Histrelin Implant	Vantas	J9225	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ibrutinib - oral	Imbruvica	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	
Idarubicin HCL - inj	Idamycin	J9211	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Idelalisib - oral	Zydelig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ifosfamide	Ifex, Mitoxana	J9208	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Imatinib - oral	Gleevec	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Imatinib - oral	Gleevec	S0088	Medical Oncology - CHEMO	Primary	ORAL	Y		
Inotuzumab Ozogamicin	Besponsa	J9229	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Interferon, alfa-2b, recombinant	Intron A	J9214	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Interferon, gamma-1b	Actimmune	J9216	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Ipilimumab	Yervoy	J9228	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Irinotecan	Camptosar	J9206	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Irinotecan Liposome	Onivyde	J9205	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Isatuximab-irfc	Sarclisa	J9227	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ivosidenib - oral	Tibsovo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ixabepilone	Ixempra	J9207	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ixazomib - oral	Ninlaro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Lanreotide	Somatuline Depot	J1930	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Lanreotide (cipla)		J1932	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Lapatinib - oral	Tykerb	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Larotrectinib - oral	Vitrakvi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Lenalidomide - oral	Revlimid	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Lenvatinib - oral	Lenvima	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Leucovorin - inj	Leucovorin Calcium	J0640	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Leucovorin - oral	Leucovorin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Leuprolide Acetate (cipla)		J1954	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Leuprolide Acetate (J1950: 3.75mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J1950	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆ Excluding Eligard	
Leuprolide Acetate (J9217: 7.5mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J9217	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆ Excluding Eligard	
Leuprolide Acetate (J9218: 1mg)	Lupron	J9218	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆ Excluding Eligard	
Leuprolide Mesylate	Camcevi	J1952	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Levoleucovorin	Fusilev	J0641	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Levoleucovorin	Khapzory	J0642	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Liposome-encapsulated combination of Daunorubicin and Cytarabine	Vyxeos	J9153	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Lomustine - oral	Gleostine, CCNU	S0178	Medical Oncology - CHEMO	Primary	ORAL	Y		
Loncastuximab tesirine-lpyl	Zynlonta	J9359	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Lorlatinib - oral	Lorbrena	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Lurbinectedin	Zepzelca	J9223	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Luspatercept-aamt	Reblozyl	J0896	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Margetuximab-cmkb	Margenza	J9353	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Mechlorethamine - topical	Valchlor	J9999	Medical Oncology - CHEMO	Primary	TOPICAL	Y		
Melphalan (apotex)		J9249	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New manufacture code: J9249 for Melphalan, effective: 04/01/24

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Melphalan (hepzato)		J9248	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New manufacture code: J9248 for Melphalan, effective: 04/01/24
Melphalan HCL - inj	Evomela	J9246	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Melphalan HCL - NOS inj	Alkeran	J9245	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Mesna	Mesnex	J9209	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Methotrexate (accord)		J9255	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Methotrexate Sodium (J9250: 5mg)	Folex, Methotrexate	J9250	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Methotrexate Sodium, 50mg		J9260	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Midostaurin - oral	Rydapt	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Mirvetuximab Soravtansine-gynx	Elahere	J9063	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Mitomycin	Jelmyto	J9281	Medical Oncology - CHEMO	Primary	PYELOCALYCEAL	Y		Medicare Part B
Mitomycin	Mutamycin	J9280	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Mitotane - oral	Lysodren	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Mitoxantrone HCL	Novantrone	J9293	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Mobocertinib - oral	Exkivity	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Mogamulizumab-kpkc	Poteligeo	J9204	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Momelotinib - oral	Ojjaara	J8499	Medical Oncology - CHEMO	Primary	ORAL	Y		J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24
Momelotinib - oral	Ojjaara	C9399	Medical Oncology - CHEMO	Primary	ORAL	Y		J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24
Momelotinib - oral	Ojjaara	J9999	Medical Oncology - CHEMO	Primary	ORAL	Y		J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24
Mosunetuzumab-axgb	Lunsumio	J9350	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Moxetumomab pasudotox-tdfk	Lumoxiti	J9313	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Nadofaragen Firadenovec-vncg	Adstiladrin	J9029	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Naxitamab-ggqk	Danyelza	J9348	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Necitumumab	Portrazza	J9295	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Nelarabine	Arranon	J9261	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Neratinib - oral	Nerlynx	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Netupitant/Palonosetron - oral	Akynzeo	J8655	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y		
Nilotinib - oral	Tasigna	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Niraparib - oral	Zejula	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Niraparib and Abiraterone Acetate - Oral	Akeega	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Nirogacestat - oral	Ogsiveo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Nivolumab	Opdivo	J9299	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Nivolumab and Relatlimab-rmbw	Opdualag	J9298	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Obinutuzumab	Gazyva	J9301	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Octreotide depot	Sandostatin	J2353	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Octreotide depot	Sandostatin	J2353	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Octreotide non-depot	Sandostatin	J2354	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	
Ofatumumab	Arzerra	J9302	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Olaparib - oral	Lynparza	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Olutasidenib - oral	Rezlidhia	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Omacetaxine	Synribo	J9262	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Osimertinib - oral	Tagrisso	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Oxaliplatin	Eloxatin	J9263	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Paclitaxel	Nov-Onxol, Taxol	J9267	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Paclitaxel (albumin-bound)	Abraxane	J9264	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Paclitaxel albumin-bound (american regent)		J9259	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Paclitaxel protein-bound (teva)		J9258	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pacritinib - oral	Vonjo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Palbociclib - oral	Ibrance	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Palonosetron	Aloxi	J2469	Medical Oncology - SPORT	Supportive - Antiemetic	INJECTABLE	Y		
Pamidronate Disodium	Aredia	J2430	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Panitumumab	Vectibix	J9303	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pazopanib - oral	Votrient	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Pegaspargase	Oncaspar	J9266	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta	J2506	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-appf	Nyvepria	Q5122	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-bmez	Zixtenzo	Q5120	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-cbqv	Udenyca	Q5111	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-fpgk	Stimufend	Q5127	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-jmdb	Fulphila	Q5108	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Pegfilgrastim-pbbk	Fynetra	Q5130	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Peginterferon, alfa-2a	Pegasys	S0145	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Pembrolizumab	Keytruda	J9271	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed	Alimta, Pemetrexed not otherwise specified	J9305	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed	Pemfexy	J9304	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (accord)		J9296	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (bluepoint)		J9322	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (hospira)		J9323	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (novaplus / hospira)		J9294	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (pemrydi rtu)		J9324	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (sandoz)		J9297	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemetrexed (teva)		J9314	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pemigatinib - oral	Pemazyre	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Pentostatin	Nipent	J9268	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pertuzumab	Perjeta	J9306	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pertuzumab / trastuzumab / hyaluronidase-zzxf	Phesgo	J9316	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pexidartinib - oral	Turalio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Pirtobrutinib - oral	Jaypirca	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Polatuzumab vedotin-piiq	Polivy	J9309	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pomalidomide - oral	Pomalyst	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ponatinib - oral	Iclusig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Porfimer Sodium	Photofrin	J9600	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pralatrexate	Folotyng	J9307	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Pralsetinib - oral	Gavreto	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Procarbazine - oral	Matulane	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Procarbazine - oral	Matulane	S0182	Medical Oncology - CHEMO	Primary	ORAL	Y		
Quizartinib - oral	Vanflyta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ramucirumab	Cyramza	J9308	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Regorafenib - oral	Stivarga	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Relugolix - oral	Orgovyx	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Reprotrectinib - oral	Augtyro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Retifanlimab-dlwr	Zynyz	J9345	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ribociclib - oral	Kisqali	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ripretinib - oral	Qinlock	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Rituximab	Rituxan	J9312	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Rituximab and Hyaluronidase Human	Rituxan Hycela	J9311	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Rituximab-abbs	Truxima	Q5115	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Rituximab-arrx	Riabni	Q5123	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Rituximab-pvvr	Ruxience	Q5119	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	◆	
Rolapitant - oral	Varubi	J8670	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y		
Romidepsin (lyophilized)	Istodax	J9319	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Romidepsin (non-lyophilized)		J9318	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ropeginterferon alfa-2b-njft	Besremi	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Ropeginterferon alfa-2b-njft	Besremi	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Rucaparib - oral	Rubraca	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ruxolitinib - oral	Jakafi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	
Sacituzumab govitecan-hziy	Trodelyv	J9317	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Sargramostim	Leukine	J2820	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Selinexor - oral	Xpovio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Selpercatinib - oral	Retevmo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Selumetinib - oral	Koselugo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	
Siltuximab	Sylvant	J2860	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Sipuleucel-T	Provenge	Q2043	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Sirolimus protein-bound particles for injectable suspension (albumin bound)	Fyarro	J9331	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Sodium Thiosulfate Injection	Pedmark	J0208	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Sodium Thiosulfate injection (hope)		J0209	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		New manufacturer code: J0209 for Sodium Thiosulfate effective: 04/01/24
Sonidegib - oral	Odomzo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Sorafenib Tosylate - oral	Nexavar	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Sotorasib - oral	Lumakras	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Streptozocin	Zanosar	J9320	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Sunitinib - oral	Sutent	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Tafasitamab-cxix	Monjuvi	J9349	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Tagraxofusp-erzs	Elzonris	J9269	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Talazoparib - oral	Talzenna	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Talimogene Laherparepvec	Imlygic	J9325	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Talquetamab-tgvs	Talvey	J3055	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24
Talquetamab-tgvs	Talvey	C9163	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24
Talquetamab-tgvs	Talvey	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24
Tazemetostat - oral	Tazverik	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Tbo-filgrastim	Granix	J1447	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Tebentafusp-tebn	Kimtrak	J9274	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Teclistamab-cqyv	Tecvayli	J9380	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Telotristat ethyl - oral	Xermelo	J8499	Medical Oncology - SPORT	Supportive	ORAL	Y		
Temozolomide - inj	Temodar	J9328	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Temozolomide - oral	Temodar	J8700	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B
Temsirolimus	Torisel	J9330	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Teniposide	Vumon	Q2017	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Tepotinib - oral	Tepmetko	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Thalidomide - oral	Thalomid	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	◆	
Thiotepa	Thioplex	J9340	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Tisotumab vedotin-tftv	Tivdak	J9273	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Tivozanib - oral	Fotivda	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Tocilizumab	Actemra	J3262	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	Supportive pathway for the use of Actemra for CAR-T induced CRS
Tocilizumab	Actemra	J3262	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	◆	
Tocilizumab-bavi	Tofidence	Q5133	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24
Tocilizumab-bavi	Tofidence	Q5133	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS.
Tocilizumab-bavi	Tofidence	C9399	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Tocilizumab-bavi	Tofidence	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS.
Tocilizumab-bavi	Tofidence	J9999	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24
Tocilizumab-bavi	Tofidence	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS.
Topotecan - inj	Hycamtin	J9351	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Topotecan - oral	Hycamtin	J8705	Medical Oncology - CHEMO	Primary	ORAL	Y		Medicare Part B
Toripalimab-tpzi	Loqtorzi	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Toripalimab-tpzi	Loqtorzi	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Trabectedin	Yondelis	J9352	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Trametinib - oral	Mekinist	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Trametinib - powder for suspension	Mekinist	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Trastuzumab	Herceptin	J9355	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	J9356	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Trastuzumab-anns	Kanjinti	Q5117	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		
Trastuzumab-dkst	Ogivri	Q5114	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		
Trastuzumab-dttb	Ontruzant	Q5112	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		
Trastuzumab-pkrb	Herzuma	Q5113	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		
Trastuzumab-qyyp	Trazimera	Q5116	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y		
Tremelimumab-actl	Imjudo	J9347	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Trifluridine/Tipiracil - oral	Lonsurf	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Trilaciclib	Cosela	J1448	Medical Oncology - SPORT	Supportive	INJECTABLE	Y		
Triptorelin Pamoate	Trelstar	J3315	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Tucatinib - oral	Tukysa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Valrubicin	Valstar	J9357	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Vandetanib - oral	Caprelsa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Vemurafenib - oral	Zelboraf	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Venetoclax - oral	Venclexta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		

Effective Date: 04/01/2024

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	1199 SEIU National Benefit Fund	Dual Indication Symbol - 1199	Drug Comments
Vinblastine Sulfate	Velban	J9360	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Vincristine Sulfate	Oncovin, Vincasar PFS	J9370	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Vinorelbine Tartrate	Navelbine	J9390	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Vismodegib - oral	Erivedge	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Vorinostat - oral	Zolinza	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Zanubrutinib - oral	Brukensa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y		
Ziv-Aflibercept	Zaltrap	J9400	Medical Oncology - CHEMO	Primary	INJECTABLE	Y		
Zoledronic Acid	Zoledronic Acid	J3489	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	◆	